Dup15q症候群治療薬の世界市場:疫学予測

◆英語タイトル:Dup15q Syndrome - Epidemiology Forecast - 2030
◆商品コード:DELV20JU195
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年7月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(195名様閲覧)USD3,750 ⇒換算¥393,750見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算¥590,625見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Dup15q Syndrome – Epidemiology Forecast–2030’ report delivers an in-depth understanding of the Dup15q syndrome, historical and forecasted epidemiology as well as the Dup15q syndrome trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Dup15q Syndrome Disease Understanding
Dup15q syndrome is a clinically identifiable syndrome that results from the duplication (or multiplication) of a portion of chromosome 15.

Each chromosome has unique regions or bands that contain genes, and each band is labeled numerically.The extra genetic material known as Dup15q syndrome contains the bands on chromosome 15 at the q arm labeled 11.2–13.1 (also referred to as the Prader-Willi/Angelman critical region [PWACR]). It can span past these bands but must contain the 11.2–13.1 region to be identified as Dup15q syndrome.The duplications occur by one of the two mechanisms isodicentric 15 chromosome [idic (15)], or an interstitial duplication 15 [int dup(15)].

The syndrome is characterized by hypotonia and gross and fine motor delays, variable intellectual disability (ID), autism spectrum disorder (ASD), and epilepsy, including infantile spasms. These characteristics of the disease vary from patient to patient and are influenced by parent-of-origin of the duplication and number of copies of the PWACR.

Dup15q Syndrome Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Dup15q Syndrome in the 7MM, Total Diagnosed Prevalent Population of Dup15q Syndrome in the 7MM, and Type-specific Diagnosed Prevalent Population of Dup15q Syndrome in the 7MM scenario of Dup15q syndrome in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Dup15q Syndrome Detailed Epidemiology Segmentation
Total prevalent cases of Dup15q syndrome in the 7MM was found to be 45,884 in 2017.
Total prevalent cases of Dup15q syndrome in the US were found to be 22,077 in 2017.
Total diagnosed prevalent cases of Dup15q syndrome in the US were found to be 4,415 in 2017.
Among the European 5 countries, Germany had the highest diagnosed population of Dup15q syndrome with 793 cases, followed by the United Kingdom and Italy respectively. On the other hand, Spain had the lowest population of 323 cases in 2017.
In 2017, out of the total diagnosed cases (4,415) in the US for Dup15q syndrome, 2,649 and 1,766 cases were contributed by idic (15) and int dup (15), respectively.
Japan had 8,374 prevalent cases of Dup15q syndrome in 2017. Out, of these cases, approximately 20% were the diagnosed population.
Scope of the Report
The report covers the descriptive overview of Dup15q syndrome, explaining its signs and symptoms, genes associated with the disease and currently available therapies.
The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The report assesses the disease risk and burden and highlights the unmet needs of Dup15q syndrome.
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Population of Dup15q syndrome, Total Diagnosed Prevalent Population of Dup15q syndrome, and Type-specific Diagnosed Prevalent Population of Dup15q syndrome.
Report Highlights
11-Year Forecast of Dup15q Syndrome
7MM Coverage
Total Prevalent Population of Dup15q Syndrome
Total Diagnosed Prevalent Population of Dup15q Syndrome
Type-specific Diagnosed Prevalent Population of Dup15q Syndrome
Key Questions Answered
What is the disease risk, burden and unmet needs of Dup15q syndrome?
What is the historical Dup15q syndrome patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
What would be the forecasted patient pool of Dup15q syndrome at the 7MM level?
What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Dup15q syndrome?
Out of the above-mentioned countries, which country would have the highest prevalent population of Dup15q syndrome during the forecast period (2020–2030)?
At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?
Reasons to buy
The Dup15q syndrome report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the 7MM Dup15q syndrome epidemiology forecast.
The Dup15q syndrome epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
The Dup15q syndrome epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.
Key Assessments
Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population
Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2017–2030

【レポートの目次】

1. Key Insights

2. Executive Summary of Dup15q Syndrome

3. Dup15q Syndrome Epidemiology Overview at a Glance

3.1. Epidemiology Share (%) Distribution of Dup15q Syndrome in 2017

3.2. Epidemiology Share (%) Distribution of Dup15q Syndrome in 2030

4. Disease Background and Overview: Dup15q Syndrome

4.1. Introduction

4.2. Signs, Symptoms and Characteristics

4.3. Chromosome 15

4.4. Chromosome Abnormalities Associated with Dup15q Syndrome

4.5. Genes Associated with Dup15q Syndrome

4.6. Quantitative Electrophysiological Biomarker of Dup15q Syndrome

4.7. Diagnosis

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. KOL Views

5.3. Epidemiology Forecast Assumptions

5.4. Epidemiology Methodology

5.5. Total Prevalent Cases of Dup15q Syndrome in the 7MM

5.6. Total Diagnosed Prevalent Cases of Dup15q Syndrome in the 7MM

6. United States Epidemiology

6.1. Assumptions and Rationale

6.2. Total Prevalent Cases of Dup15q Syndrome in the United States

6.3. Total Diagnosed Prevalent Cases of Dup15q Syndrome in the United States

6.4. Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in the United States

7. EU5 Epidemiology

7.1. Assumptions and Rationale

7.2. Germany Epidemiology

7.2.1. Total Prevalent Cases of Dup15q Syndrome in Germany

7.2.2. Total Diagnosed Prevalent Cases of Dup15q Syndrome in Germany

7.2.3. Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in Germany

7.3. France Epidemiology

7.3.1. Total Prevalent Cases of Dup15q Syndrome in France

7.3.2. Total Diagnosed Prevalent Cases of Dup15q Syndrome in France

7.3.3. Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in France

7.4. Italy Epidemiology

7.4.1. Total Prevalent Cases of Dup15q Syndrome in Italy

7.4.2. Total Diagnosed Prevalent Cases of Dup15q Syndrome in Italy

7.4.3. Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in Italy

7.5. Spain Epidemiology

7.5.1. Total Prevalent Cases of Dup15q Syndrome in Spain

7.5.2. Total Diagnosed Prevalent Cases of Dup15q Syndrome in Spain

7.5.3. Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in Spain

7.6. United Kingdom Epidemiology

7.6.1. Total Prevalent Cases of Dup15q Syndrome in the UK

7.6.2. Total Diagnosed Prevalent Cases of Dup15q Syndrome in the UK

7.6.3. Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in the UK

8. Japan Epidemiology

8.1. Assumptions and Rationale

8.2. Total Prevalent Cases of Dup15q Syndrome in Japan

8.3. Total Diagnosed Prevalent Cases of Dup15q Syndrome in Japan

8.4. Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in Japan

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Table 1 Summary of Dup15q Syndrome, Epidemiology and Key Events (2017–2030)

Table 2 Frequency of the main clinical characteristics of inv dup(15) or idic(15) syndrome

Table 3 Genomic testing used in 15q duplication and related disorders (Dup15q)

Table 4 Total Prevalent Cases of Dup15q Syndrome in the 7MM (2017–2030)

Table 5 Total Diagnosed Prevalent Cases of Dup15q Syndrome in the 7MM (2017–2030)

Table 6 Total Prevalent Cases of Dup15q Syndrome in the United States (2017–2030)

Table 7 Total Diagnosed Prevalent Cases of Dup15q Syndrome in the United States (2017–2030)

Table 8 Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in the United States (2017–2030)

Table 9 Total Prevalent Cases of Dup15q Syndrome in Germany (2017–2030)

Table 10 Total Diagnosed Prevalent Cases of Dup15q Syndrome in Germany (2017–2030)

Table 11 Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in Germany (2017–2030)

Table 12 Total Prevalent Cases of Dup15q Syndrome in France (2017–2030)

Table 13 Total Prevalent Cases of Dup15q Syndrome in France (2017–2030)

Table 14 Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in France (2017–2030)

Table 15 Total Prevalent Cases of Dup15q Syndrome in Italy (2017–2030)

Table 16 Total Diagnosed Prevalent Cases of Dup15q Syndrome in Italy (2017–2030)

Table 17 Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in Italy (2017–2030)

Table 18 Total Prevalent Cases of Dup15q Syndrome in Spain (2017–2030)

Table 19 Total Diagnosed Prevalent Cases of Dup15q Syndrome in Spain (2017–2030)

Table 20 Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in Spain (2017–2030)

Table 21 Total Prevalent Cases of Dup15q Syndrome in the UK (2017–2030)

Table 22 Total Diagnosed Prevalent Cases of Dup15q Syndrome in the UK (2017–2030)

Table 23 Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in the UK (2017–2030)

Table 24 Total Prevalent Cases of Dup15q Syndrome in Japan (2017–2030)

Table 25 Total Diagnosed Prevalent Cases of Dup15q Syndrome in Japan (2017–2030)

Table 26 Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in Japan (2017–2030)

List of Figures

Figure 1 Signs, Symptoms and Characteristics

Figure 2 Chromosome 15

Figure 3 Chromosome abnormalities in Dup15q syndrome

Figure 4 Schematic representation of chromosome 15, showing the five recurrent breakpoints (BP), and the ~4 Mb segment that encompasses the PWS/AS critical region

Figure 5 Group averaged EEG topo plots

Figure 6 Diagnostic methods/techniques for Dup15q syndrome

Figure 7 United States KOL Views

Figure 8 United States and EU-5 KOL Views

Figure 9 United States KOL Views

Figure 10 KOL Views

Figure 11 Total Prevalent Cases of Dup15q Syndrome in the 7MM (2017–2030)

Figure 12 Total Diagnosed Prevalent Cases of Dup15q Syndrome in the 7MM (2017–2030)

Figure 13 Total Prevalent Cases of Dup15q Syndrome in the United States (2017–2030)

Figure 14 Total Diagnosed Prevalent Cases of Dup15q Syndrome in the United States (2017–2030)

Figure 15 Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in the United States (2017–2030)

Figure 16 Total Prevalent Cases of Dup15q Syndrome in Germany (2017–2030)

Figure 17 Total Diagnosed Prevalent Cases of Dup15q Syndrome in Germany (2017–2030)

Figure 18 Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in Germany (2017–2030)

Figure 19 Total Prevalent Cases of Dup15q Syndrome in France (2017–2030)

Figure 20 Total Prevalent Cases of Dup15q Syndrome in France (2017–2030)

Figure 21 Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in France (2017–2030)

Figure 22 Total Prevalent Cases of Dup15q Syndrome in Italy (2017–2030)

Figure 23 Total Diagnosed Prevalent Cases of Dup15q Syndrome in Italy (2017–2030)

Figure 24 Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in Italy (2017–2030)

Figure 25 Total Prevalent Cases of Dup15q Syndrome in Spain (2017–2030)

Figure 26 Total Diagnosed Prevalent Cases of Dup15q Syndrome in Spain (2017–2030)

Figure 27 Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in Spain (2017–2030)

Figure 28 Total Prevalent Cases of Dup15q Syndrome in the UK (2017–2030)

Figure 29 Total Diagnosed Prevalent Cases of Dup15q Syndrome in the UK (2017–2030)

Figure 30 Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in the UK (2017–2030)

Figure 31 Total Prevalent Cases of Dup15q Syndrome in Japan (2017–2030)

Figure 32 Total Diagnosed Prevalent Cases of Dup15q Syndrome in Japan (2017–2030)

Figure 33 Type-specific Diagnosed Prevalent Cases of Dup15q Syndrome in Japan (2017–2030)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[Dup15q症候群治療薬の世界市場:疫学予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆